

CTI - Anxiety Disorders January 2010



Adis Clinical Trials Insight: Ongoing Trials Status Tracking – January 2010

The table below highlights the ongoing trials whose status has changed during January 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700039248	MK-4305	Completed	II	MK 4305: therapeutic use Insomnia In patients with primary disease	Merck & Co
2 700048397	Tetrahydrocannabinol	Recruiting	IV	Tetrahydrocannabinol: therapeutic use Post-traumatic stress disorder Phase IV trial in symptomatic patients despite stable medication	
3 700032007	Paliperidone	Completed	II	Paliperidone: therapeutic use Obsessive-compulsive disorders In patients with serotonin reuptake inhibitor resistant disease	Ortho-McNeil-Janssen Pharmaceuticals
4 700038810	Eszopiclone Zolpidem	Discontinued	IV	Eszopiclone, zolpidem: pharmacokinetics Evaluating gamma-aminobutyric acid receptor binding by positron emission tomography In volunteers	Sepracor
5 700048739	Lorazepam Methylphenidate Modafinil	Completed	I	Lorazepam vs methylphenidate vs modafinil: pharmacodynamics Effect on brain activity measured by magnetoencephalography, electroencephalography and the synchronous neural interaction test In volunteers	Orasi Medical
6 700047557	Melatonin	Recruiting	II	Melatonin: therapeutic use Insomnia In volunteers with induced transient insomnia	
7 700036895	Yohimbine	Active, no longer recruiting	II/III	Yohimbine: therapeutic use Phobic disorders In combination with virtual reality exposure therapy	
8 700045750	Hydrocortisone	Completed	II	Hydrocortisone: therapeutic use Phobic disorders In patients who receiving drug in combination with behavioral therapy	
9 700018562	Hydrocortisone	Discontinued	II	Hydrocortisone: therapeutic use Post-traumatic stress disorder Efficacy of low-dose therapy in patients with chronic disease	

CTI - Anxiety Disorders January 2010



Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
10 700024357	Ramelteon	Discontinued	IV	Ramelteon: therapeutic use Sleep disorders In patients with Parkinson's disease	
11 700031552	Esmirtazapine	Completed	III	Esmirtazapine: adverse reactions Various toxicities Phase III open-label extension trial in patients with chronic primary insomnia	Merck & Co
12 700050468	Caffeine Dextromethorphan Midazolam Omeprazole PLX-4032 Warfarin	Recruiting	I	PLX-4032 + cytochrome P-450 enzyme system modulators: pharmacokinetics Effect on drug concentrations Phase I trial in patients with malignant melanoma	Roche
13 700045882	Eplivanserin	Completed	I	Eplivanserin: adverse reactions Various toxicities In children with insomnia	sanofi-aventis
14 700052654	Escitalopram Methylphenidate RO-4917523	Active, no longer recruiting	I	Escitalopram, methylphenidate, RO 4917523: pharmacodynamics Assessing effect on brain activity In volunteers	Genentech, Roche
15 700027294	Prazosin	Recruiting	III	Prazosin: therapeutic use Post-traumatic stress disorder	

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.